FI933151L - 5,10 metylentetrahydrofolsyre-cyklodextrin-inneslutningsfoereningar - Google Patents

5,10 metylentetrahydrofolsyre-cyklodextrin-inneslutningsfoereningar Download PDF

Info

Publication number
FI933151L
FI933151L FI933151A FI933151A FI933151L FI 933151 L FI933151 L FI 933151L FI 933151 A FI933151 A FI 933151A FI 933151 A FI933151 A FI 933151A FI 933151 L FI933151 L FI 933151L
Authority
FI
Finland
Prior art keywords
methylentetrahydrofolsyre
inneslutningsfoereningar
cyclodextrin
Prior art date
Application number
FI933151A
Other languages
English (en)
Other versions
FI933151A0 (fi
FI933151A7 (fi
Inventor
Hans Rudolf Mueller
Martin Ulmann
Josef Conti
Original Assignee
Eprova Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eprova Ag filed Critical Eprova Ag
Publication of FI933151A0 publication Critical patent/FI933151A0/fi
Publication of FI933151L publication Critical patent/FI933151L/fi
Publication of FI933151A7 publication Critical patent/FI933151A7/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Ink Jet (AREA)
  • Ink Jet Recording Methods And Recording Media Thereof (AREA)
FI933151A 1992-07-13 1993-07-09 5,10-metyleenitetrahydrofoolihappo-syklodekstriini-sulkeumayhdisteet FI933151A7 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH2192/92A CH684644A5 (de) 1992-07-13 1992-07-13 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.

Publications (3)

Publication Number Publication Date
FI933151A0 FI933151A0 (fi) 1993-07-09
FI933151L true FI933151L (fi) 1994-01-14
FI933151A7 FI933151A7 (fi) 1994-01-14

Family

ID=4228046

Family Applications (1)

Application Number Title Priority Date Filing Date
FI933151A FI933151A7 (fi) 1992-07-13 1993-07-09 5,10-metyleenitetrahydrofoolihappo-syklodekstriini-sulkeumayhdisteet

Country Status (18)

Country Link
US (1) US5455236A (fi)
EP (1) EP0579996B1 (fi)
JP (1) JP2667354B2 (fi)
KR (1) KR100217788B1 (fi)
CN (1) CN1032901C (fi)
AT (1) ATE121949T1 (fi)
AU (1) AU661591B2 (fi)
CA (1) CA2100126C (fi)
CH (1) CH684644A5 (fi)
DE (1) DE59300176D1 (fi)
DK (1) DK0579996T3 (fi)
ES (1) ES2072163T3 (fi)
FI (1) FI933151A7 (fi)
HU (2) HU212665B (fi)
NO (1) NO303715B1 (fi)
RU (1) RU2135519C1 (fi)
TW (1) TW379142B (fi)
ZA (1) ZA934907B (fi)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906981A (en) * 1996-06-04 1999-05-25 Troy Corporation Halopropargyl inclusion complexes
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
CN1095472C (zh) * 2000-04-17 2002-12-04 上海复康医药科技发展有限公司 叶酸-多聚糖复合物,其制备方法和以该复合物为活性成分的药物组合物
DE602005026352D1 (de) * 2004-09-15 2011-03-31 Nipro Corp Wässrige, stabile (6S)-Folinsäurelösung zur Injektion
CN101657203B (zh) * 2007-03-02 2012-09-05 卧龙岗大学 抗癌药的组合物及递送方法
CN101235102B (zh) * 2008-02-18 2010-11-03 南昌航空大学 一种叶酸偶联羟丙基壳聚糖纳米微粒的制备方法
CN102000345A (zh) * 2010-11-16 2011-04-06 广西大学 包合态的叶酸/β-环糊精组合物及其制备方法
CN102258788B (zh) * 2011-06-13 2012-11-07 南开大学 一种靶向传递阿霉素抗癌药的组装体及其制备方法
EP2837631A1 (en) 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
RU2537246C1 (ru) * 2013-10-17 2014-12-27 Федеральное государственное бюджетное учреждение "Научный центр клинической и эскпериментальной медицины" Сибирского отделения Российской академии медицинских наук ФГБУ "НЦКЭМ" СО РАМН Способ получения биотинилированного производного окисленного декстрана
EP2878600B1 (en) 2013-12-02 2018-06-27 Cerbios-Pharma S.A. Stable complexes of an alkaline earth metal salt of N5-methyl-tetrahydrofolic acid and a polyol
JP7232815B2 (ja) 2017-08-16 2023-03-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 5,10-メチレン-(6r)-テトラヒドロ葉酸を含む安定な凍結乾燥物
CN112089848A (zh) * 2020-10-27 2020-12-18 浙江诺得药业有限公司 叶酸的环糊精包合物及其制备方法
WO2023237483A1 (en) 2022-06-08 2023-12-14 Merck Patent Gmbh Concentrated solutions comprising 5,10-methylene-(6r)-tetrahydrofolic acid
EP4536188A1 (en) 2022-06-08 2025-04-16 Merck Patent GmbH Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid
IL317418A (en) 2022-06-08 2025-02-01 Merck Patent Gmbh Stable pharmaceutical preparations comprising 5,10-methylene-(6R)-tetrahydrofolic acid and NaCl
US20250319022A1 (en) 2022-06-08 2025-10-16 Merck Patent Gmbh Concentrated solutions comprising sodium 5,10-methylene-(6r)-tetrahydrofolate
CN117771389A (zh) * 2023-12-28 2024-03-29 浙江圣达生物药业股份有限公司 L-5-甲基四氢叶酸钙-γ-环糊精包合物及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0031237B1 (en) * 1979-12-19 1984-10-17 National Research Development Corporation Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
US4350659A (en) * 1981-07-30 1982-09-21 Corning Glass Works Stabilization of sensitive biologically active intermediate metabolites such as folic acid derivatives
JPS602775B2 (ja) 1981-08-28 1985-01-23 富士通株式会社 モニタ機能付大規模集積回路及びその製造方法
JPS59175432A (ja) * 1983-03-25 1984-10-04 Yatoron:Kk ジヒドロ葉酸溶液の安定化方法
JPS62281855A (ja) * 1986-05-29 1987-12-07 Daikin Ind Ltd ビタミン,ビタミン誘導体,またはホルモンを含有する包接化合物
GB8621268D0 (en) * 1986-09-03 1986-10-08 Univ Strathclyde Separation of substances
US4857530A (en) * 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
NL8901432A (nl) * 1989-06-06 1991-01-02 Pharmachemie Bv Bij koelkasttemperatuur stabiele waterige folinaatoplossing, alsmede werkwijze ter bereiding daarvan.
CA2021042A1 (en) 1989-07-21 1991-01-22 Fabrizio Marazza Salts of n ,n -methylene-5,6,7,8-tetrahydrofolic acid
DK0416232T3 (da) 1989-08-21 1995-09-18 American Cyanamid Co Stabil injicerbar farmaceutisk formulering med folsyre- og leukovorinsalte og fremgangsmåde
IT1237509B (it) 1989-10-31 1993-06-08 Magis Farmaceutici Complessi con le ciclodestrine indicati per il trattamento di tutte leforme anemiche da carenza di folati, loro preparazione e relative composizioni farmaceutiche
CH680731A5 (fi) * 1990-04-12 1992-10-30 Sapec Fine Chemicals
WO1991017660A1 (en) 1990-05-11 1991-11-28 Spears Colin P 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
US5153309A (en) * 1990-07-27 1992-10-06 The United States Of America As Represented By The Department Of Health And Human Services Process of making tetrahydropteroylpoly-l-glutamic acid derivatives
CH681303A5 (fi) 1991-01-16 1993-02-26 Eprova Ag
CA2110942A1 (en) * 1991-06-14 1992-12-23 Pharmacia & Upjohn Company Llc Imidazo¬1,5-a|quinoxalines

Also Published As

Publication number Publication date
CN1081688A (zh) 1994-02-09
DK0579996T3 (da) 1995-07-10
HUT65714A (en) 1994-07-28
FI933151A0 (fi) 1993-07-09
HU211484A9 (en) 1995-11-28
EP0579996B1 (de) 1995-05-03
ZA934907B (en) 1994-02-09
JP2667354B2 (ja) 1997-10-27
KR100217788B1 (ko) 1999-09-01
CA2100126C (en) 1998-05-05
CH684644A5 (de) 1994-11-15
CN1032901C (zh) 1996-10-02
AU661591B2 (en) 1995-07-27
HU212665B (en) 1996-09-30
US5455236A (en) 1995-10-03
CA2100126A1 (en) 1994-01-14
HU9301990D0 (en) 1993-09-28
JPH0718084A (ja) 1995-01-20
ES2072163T3 (es) 1995-07-01
NO932517D0 (no) 1993-07-09
AU4187093A (en) 1994-01-20
NO932517L (no) 1994-01-14
KR940002301A (ko) 1994-02-17
EP0579996A1 (de) 1994-01-26
FI933151A7 (fi) 1994-01-14
TW379142B (en) 2000-01-11
NO303715B1 (no) 1998-08-24
DE59300176D1 (de) 1995-06-08
RU2135519C1 (ru) 1999-08-27
ATE121949T1 (de) 1995-05-15

Similar Documents

Publication Publication Date Title
FI953489A0 (fi) 2,6-diaminopuriinijohdannaisia
FI954651A7 (fi) Mahdollisesti substituoidut 6,8-kinoliinit
NO920018D0 (no) 1,3-oksatiolannukleosidanaloger
FI923314L (fi) Substituerade cyklopropylamino-1,3,5-triaziner
FI935260A7 (fi) Telekommunikationssystem, i vilket debiteringsdatan registreras i handtelefonen
FI934610A0 (fi) Ventilsammansaettning foer roerledning, omfattande loestagbart ventilsaete
FI933151L (fi) 5,10 metylentetrahydrofolsyre-cyklodextrin-inneslutningsfoereningar
FI930296L (fi) 1,4-disubstituerade piperaziner
FI932516A7 (fi) Styrkonsol, i synnerhet foer motorfordon
NO932842D0 (no) 1,4-benzodioksanderivater
FI931747A0 (fi) Reflexkropp, isynnerhet foer vaegmarkeringar
FI931459L (fi) Sammansaettningar med 1-klor-2,2,2-trifluoretyldifluor-metyleter
DE59308564D1 (de) 2,4-Dialkyl-6-sec-alkylphenole
FI932874L (fi) 6,7-modifierade 11b-aryl-4-estrener
FI923709A0 (fi) I en saekerhetsskena laosbar vagn.
FI934928A7 (fi) Foerfarande foer framstaellning av 3,7-dialkylxantiner fraon 3-alkylxantiner
FI932396A7 (fi) Foerfarande foer framstaellning av en dubbelskyddad 2,3-hydroximetylcyklobutanol
FI931794L (fi) Monokvaternaera 2,16-bispiperidinylandrostanderivat
FI931825A7 (fi) Hydraulisk tryck- och draganordning, speciellt foer jaernvaegsskenor
FI930237L (fi) Foerfarande foer framstaellning av 4,6-dialkoxipyrimidiner
FI934317L (fi) Farmaceutiska sammansaettningar, vilka innehaoller ej-joniska ytaktiva aemnen
NO944024D0 (no) 1,2-dihydro-2-okso-pyridin
NO922732D0 (no) 3,4-dehydropiperidinderivater
FI266U1 (fi) Kapningsanordning foer aemnesbana, saosom en pappersbana
FI932595L (fi) En vattenhaltig, polymerisk, viskositet upphoejande komposition